Vytorin, Zetia Labeling Adds Precaution On Cyclosporine Coadministration
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised labeling for the Merck/Schering-Plough products recommends caution when coadministering ezetimibe and cyclosporine. In healthy patients, coadministration of cyclosporine and ezetimibe was associated with a 15% increase in cyclosporine AUC, labeling states.
You may also be interested in...
Zetia Labeling Adds Myopathy/Rhabdomyolysis Precaution
Revised labeling for Merck's lipid-lowering therapy notes most cases of rhabdomyolysis occurred in patients who had been taking statins. The skeletal muscle precaution follows the recent addition of a precaution against use with cyclosporine.
Zetia Labeling Adds Myopathy/Rhabdomyolysis Precaution
Revised labeling for Merck's lipid-lowering therapy notes most cases of rhabdomyolysis occurred in patients who had been taking statins. The skeletal muscle precaution follows the recent addition of a precaution against use with cyclosporine.
Schering/Merck Zetia 6% Market Share Is 1% Ahead Of Goal
Prescription growth for the cholesterol drug Zetia has not come at the expense of the Zetia/Zocor fixed-dose combination Vytorin, Schering says. The penetration rate for Vytorin on managed care formularies is over 75%, the company says.